CalciMedica Inc. announced that the last patient has been enrolled in its Phase 2b CARPO trial of Auxora? in acute pancreatitis (AP). Auxora is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is being developed for use in patients with acute inflammatory and immunologic illnesses.

CARPO is an international, randomized, double-blind, placebo-controlled, dose-ranging trial intended to establish Auxora's dose-response and efficacy in AP with accompanying systemic inflammatory response syndrome (SIRS). These patients have been randomized into four groups to receive either 2.0 mg/kg, 1.0 mg/kg or 0.5 mg/kg of Auxora or a dose of placebo intravenously every 24 hours for a total of three doses. CARPO protocol requires that treatment and observation of patients continue for 30 days, and the company plans to report topline data later this quarter.